

1 **The Feasibility of a Smartphone-based Digital Therapeutics for Dysarthria**
2 **after Stroke (DiDaS): Protocol for a pilot randomized controlled trial**

3

4

5 Yuyoung Kim¹, Minjung Kim¹, Jinwoo Kim^{1,2}, Tae-Jin Song^{3*}

6 ¹ HCI Lab, Yonsei University, Seoul, South Korea

7 ² HAI Corporation, Seoul, South Korea

8 ³ Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine,

9 Seoul, South Korea

10

11

12

13 * Corresponding author

14 E-mail: knstar@ewha.ac.kr (TJS)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

16 **Abstract**

17 **Background:** Dysarthria is a motor speech disorder occurring from neurological conditions
18 such as stroke. It leads to serious problems in the intelligibility of patients' speech, affecting
19 their ability to communicate, quality of life, and emotional well-being. While digital
20 therapeutic approaches for rehabilitation of dysarthria are increasing, clinical evidence of the
21 effectiveness of digital therapeutics has been lacking. A mobile application, D-ST01, has the
22 potential to enhance intensive and repetitive speech rehabilitation due to its high treatment
23 accessibility and its incorporation of gamification, tailored feedback, and interactive functions.

24 **Methods:** In our trial, 60 stroke patients with dysarthria within 30 days following the
25 occurrence of stroke will be recruited. In a 1:1 ratio, participants will be randomly assigned to
26 either the intervention group (using D-ST01 for 60 minutes/day, five days/week along with
27 usual stroke care) or the control group (usual stroke care only). This will be a single-blind study
28 in which researchers will evaluate outcome measurements while masked to treatment
29 allocation. After four weeks of treatment intervention, we will compare speech and
30 psychological changes between the two groups.

31 **Conclusions:** Our study will evaluate the feasibility of the speech treatment application D-
32 ST01 for patients with post-stroke dysarthria. In addition, it will collect evidence for
33 investigating the future efficacy of a large-scale randomized controlled trial.

34 **Trial registration number:** ClinicalTrial.gov #NCT05146765

35

36 **Introduction**

37 Stroke is one major cause of worldwide mortality and morbidity [1]. Approximately 40% of
38 stroke patients experience disability [2, 3], and more than 50% of acute stroke victims

39 experience dysarthria [4]. Dysarthria is a neurological motor speech disorder caused by weak,
40 slow, or damaged muscles in the speech-production subsystems [5]. Dysarthria can negatively
41 affect speech intelligibility [5] and communication [6], leading to abnormalities in vocal
42 quality, speed, strength, volume, tone, steadiness, or breath control [5]. Difficulty with
43 communication due to dysarthria after stroke poses a considerable barrier to involvement in
44 social activities and negatively affects the quality of life [7]. It can also lead to emotional
45 difficulties [8], including depression and anxiety.

46 Intervention for dysarthria involves speech rehabilitation strategies tailored to individual needs
47 and goals [9]. Once emergent medical situations have been settled and the patient is
48 neurologically stabilized, intensive speech treatment is prescribed. The evidence suggests that
49 early, rigorous, and repetitive speech therapy can facilitate neurological recovery [10, 11].
50 However, treatment adherence may be negatively impacted by the patients due to the tediously
51 repeating nature of current speech treatment [12]. Furthermore, since speech therapy involves
52 a substantial amount of time and effort of speech-language pathologist, patients may face
53 restrictions on therapeutic resources [13]. Currently, only about one-third of patients receive
54 sufficient speech therapy. The frequency of therapy also varies from patient to patient [14]. In
55 this context, the use of digital technologies in speech therapy is continuously expanding due to
56 its potential benefits [15].

57 Digital therapeutics (DTx) is an “evidence-based intervention using high-quality software to
58 prevent, manage, or treat a medical disorder or disease” [16]. There are several advantages to
59 using DTx for self-rehabilitation of dysarthria. DTx can provide more intensive and extended
60 self-administered speech therapy through a smartphone. Also, DTx can overcome the barriers
61 of in-clinic care by providing personalized treatment remotely regardless of time and place.
62 Gamified rehabilitation is an emerging therapeutic methodology that offers good motivation,
63 feedback, and interactivity [17] and can provide repetitive and goal-oriented programs tailored

64 to each patient's capabilities [18]. Moreover, conversational technologies can facilitate
65 repetitive tasks by providing objective and quantified performance feedback [19]. These
66 features will encourage patients to actively engage in the management of their health by
67 reducing boredom and poor compliance issues [20]. In addition, post-stroke dysarthria patients
68 can have difficulty visiting outpatient clinics due to mobility problems, insufficient family
69 support, and distance between homes and clinics. Therefore, DTx can expand access to
70 treatment [21]. A mobile system incorporating intensive, repetitive, and functional task-
71 oriented speech treatment that can be initiated even during the acute phase will be an alternative
72 to conventional rehabilitation.

73 However, evidence of the effectiveness of these treatments, particularly DTx, for post-stroke
74 dysarthria is limited due to a lack of sufficiently powered and controlled trials [22]. We
75 hypothesize that stroke patients with dysarthria treated with a speech therapy application called
76 D-ST01 for four weeks will show more improvement in dysarthria symptoms than those who
77 do not receive treatment with the D-ST01 application. Thus, our goal is to develop and test the
78 feasibility of smartphone-based speech therapy, D-ST01, for a stroke patient with dysarthria.

79 **Methods**

80 **Study design**

81 This is a single-blind, pilot randomized controlled trial with stroke patients with dysarthria
82 allotted to the intervention or control group (Fig 1 and Fig 2). All participants will be recruited
83 among stroke patients from a single stroke center (Ewha Womans University Seoul Hospital)
84 in South Korea. The trial will be conducted in accordance with the Declaration of Helsinki
85 [23]. We will thoroughly explain the purpose and the terms of the study to the participants and
86 receive written informed consent. The study received ethics approval from the Ewha Womans

87 University Seoul Hospital Institutional Review Board on December 21, 2021 (Approval
88 number: SEUMC 2021-12-011). The trial is registered with NCT05146765.

89 **Fig 1. DiDAS pilot trial schedule of enrollment, interventions, and assessments.**

90 **Fig 2. CONSORT diagram representing participant flow in the study**

91 **Inclusion procedure**

92 The stroke specialist neurologists will screen and enroll participants who meet the eligibility
93 criteria. If a participant meets the eligibility criteria and agrees to participate, a patient
94 information sheet will be delivered to the research coordinator to confirm the patient's
95 eligibility. The principal investigator will inform the study process to the participants, including
96 the various treatment options available for their symptoms and the risks and benefits of the
97 intervention. Then, the principal investigator will obtain consent from the participant following
98 Research Ethics Committee guidance and Clinical Practice Standards. Table 1 presents this
99 study's eligibility criteria.

100 **Table 1. Inclusion and exclusion criteria.**

Inclusion criteria.
1. Medically stable dysarthria patients, as diagnosed by a stroke specialty neurologist.
2. less than the one-month onset of stroke.
3. Sufficient cognitive function to use speech therapy applications (Mini-Mental State Exam score of $21 \geq$).
4. As judged by the clinician, patients with sufficient ability in vision, hearing, communication skills, and motor skills to participate in this study.
Exclusion criteria
1. Unable to use application or conduct speech assessment due to severe speech impairment.
2. Co-existing progressive neurological conditions such as dementia.
3. Diagnosed with severe mental disorders (e.g., depression, schizophrenia, alcohol addiction, or drug addiction).
4. Receives concomitant treatment during the study, which can affect trial results (e.g., dementia treatment and sleeping pills).
5. Is illiterate.

101

102 **Randomization**

103 Participants will be randomly allocated with a 1:1 ratio to receive treatment with the speech
104 therapy application along with usual stroke care (the intervention group) or usual stroke care
105 only (the control group). The randomization will be performed by the research officer (not
106 involved in this study) of the clinical trial center of Seoul Hospital, Ewha Womans University.
107 An Excel spreadsheet will be used to generate the random list. The randomization will be
108 created using reasonably sized permuted blocks, and the block size will not be disclosed until
109 the completion of the trial to ensure masking.

110 **Blinding**

111 Due to the interactive nature of rehabilitation, it is not possible to mask the intervention to
112 patients and research investigators. Therefore, we will blind the separate outcome assessors,
113 who will not be involved in the treatment procedures, to minimize bias. In order to maintain
114 blindness, participants will also be advised not to disclose their assigned group to the outcome
115 assessors.

116 **Interventions**

117 **Patients allocated to the control group** will receive "usual stroke care" including medical
118 treatment and routine rehabilitation therapy for four weeks. Clinicians and speech-language
119 pathologists will provide usual stroke care based on conventional stroke therapy guidelines
120 [24, 25] and patient needs. This care is expected to be set according to clinical needs as agreed
121 between clinicians and patients and modified according to progress. Participants in this group
122 will only receive usual stroke care and will not use the mobile application, D-ST01.

123 **Participants in the intervention group** will use the speech therapy application, D-ST01, in
124 addition to receiving usual stroke care (see S3). D-ST01 is a mobile application that delivers
125 speech therapy to patients with post-stroke dysarthria, allowing them to rehabilitate
126 independently. As repetitive and intensive training is crucial in speech therapy, the system

127 features gamification, tailored feedback, and interactive functions designed to motivate patients
128 to persist with constant speech training. Ten different types of speech exercises are provided
129 in the program, with the goal of enhancing speech intelligibility. Participants will perform the
130 speech exercises for one hour per day, five days per week, for four consecutive weeks. They
131 may complete the speech exercises all at once or split them into several sessions. The
132 application provides both written and verbal instructions for each exercise in order to support
133 participants with no or little experience in using a mobile application. The research team will
134 help participants to install the application and will provide a practice session at baseline to
135 enhance participants' understanding of and engagement with the intervention. Furthermore,
136 participants will be encouraged to reach out to the research team if any issues arise regarding
137 the use of the application.

138 **Data collection**

139 The primary outcome will be indicated by changes in repeated measured data concerning
140 speech intelligibility between the intervention group and control group from baseline to 4-
141 weeks post-intervention.

142 Speech intelligibility will be assessed by reading "Gaeul" [26], a text commonly used to
143 evaluate speech disorders in Korea. For future analysis and confirmation, all speech evaluations
144 will be recorded using a high-quality digital recorder (SONY ICD-UX560F). Then, three
145 researchers will listen to the continuous speech of participants and calculate the average by
146 evaluating their intelligibility with a score of 0 (normal) to 6 (unintelligible) [27].

147 Secondary outcome measures will be evaluated at baseline and after 4 weeks. These will
148 include percentage of consonants correct [28, 29], oral mechanism test [30], oral-
149 diadochokinesis [31], maximum phonation time [32] and phonation evaluation [30]. The
150 experienced speech-language pathologists (with a minimum experience of 6 years), blinded to
151 the participants' allocation, will be asked to assess various aspects of participants' speech.

152 The tertiary outcome will be indicated by changes in a stroke scale and psychological scales.
153 The qualified researchers will evaluate the National Institute of Health Stroke Scale [33]. In
154 addition, we will evaluate patient-reported outcomes concerning depression (Patient Health
155 Questionnaire-9) [34], anxiety (Generalized Anxiety disorder-7) [35], quality of life (Euro
156 Quality of Life) [36], and self-efficacy (Modified Computer Self-Efficacy Scale) [37].
157 In the last phase of the study, the patients who used the application will complete a system
158 usability scale questionnaire to uncover their experience with the smartphone-based speech
159 therapy [38]. Details of the outcome measures are described in the S2 protocol file.

160 **Analyses**

161 **Sample size**

162 The purpose of this study protocol is to investigate the feasibility of digital speech therapy for
163 post-stroke dysarthria, and the results will be used for future power analyses of a larger study.
164 A power calculation was carried out by using G*power 3.0 given the following: 1) power of
165 80%, 2) a two-sided alpha of 0.05, 3) an estimated effect size of 0.8, and 4) a 1:1 intervention
166 allocation. Thus, each group will need a sample size of 26 participants.
167 The effect size was calculated by referring to the results of the existing study. Moon and Won
168 studied the effectiveness of smartphone-based speech exercises for 14 acute stroke patients
169 [39]. As a result of calculating the power for the primary outcome with a significance level of
170 0.05 and 26 participants per group, the oral mechanism was 98%, and oral-diadochokinetic was
171 98%. Therefore, the use of a major primary outcome, oral mechanism [30], and oral-
172 diadochokinetic [40, 41] for 52 participants are expected to be appropriate in this study. The
173 power analysis is described in detail in S2 protocol file.
174 A total of 60 participants (30 in each group) will be recruited, considering 15% dropout rate.

175 **Statistical methods**

176 All analyses, including a descriptive analysis of demographic and outcome data, will be
177 performed in SPSS (version 25; IBM New York).

178 An intention-to-treat analysis will be conducted in order to compare outcome measures. First,
179 the Shapiro-Wilk test will be used to examine whether the distribution of continuous variables
180 is normal. Depending on normality, a parametric test (which assumes normal distribution) or
181 non-parametric equivalents (not satisfied with a normality distribution) will be performed. The
182 general characteristics of the two groups will be analyzed with the independent t-test or the
183 Mann-Whitney U test.

184 Next, paired comparison within the groups (pre- and post-intervention) will be analyzed using
185 the paired t-test or the Wilcoxon signed-rank test. A repeated measures analysis of variance
186 will be performed for each result, taking into account the within-subject factor time (Pre; Post)
187 and the between-subject factor group (Intervention group; Control group). Moreover, a linear
188 mixed model that controls for baseline National Institute of Health Stroke Scale and the
189 location of cerebral infarction as fixed effects will be performed. Statistical significance will
190 be set at $p < 0.05$. The Last Observation Carried Forward method [42] will be performed to
191 manage the missing data.

192 **Monitoring**

193 A data monitoring committee is not needed since there is no risk that mobile-based intervention
194 content will adversely affect participants. Participants may withdraw consent at any time for
195 any reason. Should participants withdraw, they can discontinue the trial without any
196 consequences. Additionally, if a participant requires immediate medical attention, the
197 researchers may withdraw them from the trial.

198 **Discussion**

199 Our protocol is for a randomized clinical trial of a digital therapeutic provided to stroke patients
200 with dysarthria. Although intensive and repetitive speech therapy is recommended due to its
201 apparent benefits, post-stroke dysarthria treatment remains under-researched [43, 44].
202 Insufficient methodological rigor, a paucity of studies, and a narrow scope of evaluated
203 interventions limit the available evidence concerning dysarthria treatment [22, 45].
204 Several studies have adopted traditional speech interventions, including behavioral techniques,
205 breathing, non-speech oro-motor exercises, Lee Silverman Voice Treatment, repetition training
206 of sound, and progressive reading [46]. In a study by Mahler and Ramig [47], reading phrases
207 and Lee Silverman Voice Treatment, which targets high phonatory effort to improve speech
208 skills, were employed in the intervention. Four patients with dysarthria at nine months or more
209 post-stroke received 16 one-hour sessions over four weeks and showed positive responses. Park
210 et al.[48] verified the effect of speech therapy on patients at least six months post-onset of
211 stroke. The intervention consisted of a 60-minute practice, four times per week, for four weeks
212 (16 sessions). The treatment in this study focused on enhancing speech intelligibility with
213 repetitive acoustic-phonetic adjustments.

214 As in previous studies, our intervention is based on traditional treatments that incorporate
215 motor learning principles (rigorous repetitive training and feedback) [44] and neuroplasticity
216 (repetition, motivation, and reward) [10]. In addition, the treatment duration of one hour, five
217 times per week, for four weeks is consistent with previous behavioral interventions in post-
218 stroke dysarthria [47-50]. However, our protocol differs in enrolling stroke patients from acute
219 to subacute period. The prognosis of speech treatment in the first few months is important since
220 the stroke onset could be critical to reducing recovery time [51]. Nonetheless, the evidence of
221 post-stroke dysarthria in the acute phase is weak [52]. Therefore, the results of our protocol
222 will prove whether the smartphone-based intervention used in this study can help stroke
223 patients with dysarthria to improve their conditions in the acute to subacute period.

224 As traditional speech therapy continues to fall short of meeting the needs of dysarthric patients,
225 the use of technology in speech rehabilitation has increased, providing new opportunities to
226 overcome the limits of face-to-face treatments. As in all post-stroke rehabilitation, inadequate
227 long-term adherence is a problem in speech therapy [53, 54]. Patients may exercise less
228 frequently than suggested [55], struggle to achieve daily treatment goals [56], or even quit
229 therapy entirely [54]. Digital therapeutics available in home settings are expected to promote
230 high-intensity programs [8], which allow self-management of speech training, facilitate access
231 to care, improve treatment engagement, and lower care costs [16, 57]. Despite the various
232 advantages of technology-based speech therapy, evidence that such therapies are effective in
233 patients with dysarthria is lacking. Our D-ST01 intervention is novel and innovative in that it
234 is composed of several technical features to help with post-stroke dysarthria treatment. D-ST01
235 adopts gamification elements, responding to users' speech in real-time and providing points for
236 each task. Since adherence to rehabilitation in stroke patients remains an unmet need, the
237 gamified intervention can make training more enjoyable. As a result, patients' increased
238 intrinsic motivation can lead to treatment engagement [58, 59]. Technology also enables
239 accurate measurement of several parameters of user interactions and generates valuable
240 feedback to improve the performance of goal-oriented tasks [60]. Participants in this study will
241 receive real-time performance feedback for each exercise (e.g., "Speak louder!"), as well as
242 summary feedback on a daily and weekly basis. The use of this personalized feedback structure
243 is in line with previous findings [44, 61], which indicate that it reinforces positive behaviors
244 and enhances performance. Therefore, the goal of this randomized controlled clinical trial is to
245 identify the feasibility of a smartphone-based post-stroke dysarthria treatment that incorporates
246 gamification, tailored feedback, and interactive functions.

247 This protocol has a few limitations. First, although this is a pilot trial, the sample size is small.
248 Therefore, generalization may be limited. Second, participants do not receive face-to-face

249 treatment during the intervention. Under these circumstances, patients' motivation might
250 decrease due to the lack of interpersonal interaction, resulting in a higher-than-expected
251 dropout rate [54, 60]. To address this limitation, we will monitor user data periodically and
252 manage participants through intermittent phone coaching and messaging in order to reduce the
253 number of dropouts. Third, since our D-ST01 app runs only in Korean, the result of the study
254 may not be applicable to stroke patients in other countries. In addition, the study has limited
255 generalizability to the population of patients who are incapable of using or accessing
256 smartphone technology. This issue is particularly prevalent in the elderly population, which is
257 the main target of our study, given that people over 60 account for the majority of stroke cases
258 [61]. However, the findings of this study will form a basis for understanding elderly stroke
259 patients and developing future speech rehabilitation programs for the aging population. Despite
260 these limitations, the findings from this study will inform decisions about effect size estimates
261 and power analysis in future studies.

262 **Dissemination**

263 Our study protocol will convey key findings and implications to stakeholders related to digital
264 therapeutics for post-stroke dysarthria. The results will be used as evidence for large-scale
265 clinical trials in the future and will be submitted and published in peer-reviewed scientific
266 journals and global conferences.

267 **Supporting information**

268 **S1 Checklist. SPIRT 2013 checklist.**

269 (DOCX)

270 **S2 Protocol.**

271 (DOCX)

272 **S3 TIDieR checklist.**

273 (DOCX)

274 **Author contributions**

275 **Conceptualization:** Yuyoung Kim, Minjung Kim, Tae-Jin Song

276 **Methodology:** Yuyoung Kim, Minjung Kim, Tae-Jin Song

277 **Writing – original draft:** Yuyoung Kim, Minjung Kim

278 **Writing – review & editing:** Yuyoung Kim, Minjung Kim, Tae-Jin Song

279 **Supervision:** Yuyoung Kim, Minjung Kim, Tae-Jin Song, Jinwoo Kim

280 **References**

281 1. Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke

282 Organization (WSO): Global Stroke Fact Sheet 2022. *International Journal of Stroke*.

283 2022;17(1):18-29. doi: 10.1177/17474930211065917. PubMed PMID: 34986727.

284 2. Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-Related Quality of

285 Life Among Long-Term Survivors of Stroke. *Stroke*. 2000;31(2):440-7. doi:

286 doi:10.1161/01.STR.31.2.440.

287 3. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long-term disability after

288 first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-

289 1990. *Stroke*. 2002;33(4):1034-40. doi: 10.1161/01.str.0000012515.66889.24. PubMed

290 PMID: 11935057.

291 4. Flowers HL, Silver FL, Fang J, Rochon E, Martino R. The incidence, co-occurrence, and

292 predictors of dysphagia, dysarthria, and aphasia after first-ever acute ischemic stroke. *Journal*

293 *of communication disorders*. 2013;46(3):238-48. Epub 20130412. doi:

294 10.1016/j.jcomdis.2013.04.001. PubMed PMID: 23642855.

- 295 5. Duffy JR. Motor speech disorders : substrates, differential diagnosis, and management.
296 Fourth edition. ed. St. Louis, Missouri: Elsevier; 2020.
- 297 6. Pamela Comrie CMJM. The influence of acquired dysarthria on conversational turn-
298 taking. *Clinical Linguistics & Phonetics*. 2001;15(5):383-98. doi:
299 10.1080/02699200110036380.
- 300 7. Mackenzie C, Kelly S, Paton G, Brady M, Muir M. The Living with Dysarthria group for
301 post-stroke dysarthria: the participant voice. *International journal of language &*
302 *communication disorders*. 2013;48(4):402-20. Epub 20130417. doi: 10.1111/1460-
303 6984.12017. PubMed PMID: 23889836.
- 304 8. Dickson S, Barbour RS, Brady M, Clark AM, Paton G. Patients' experiences of disruptions
305 associated with post-stroke dysarthria. *International Journal of Language & Communication*
306 *Disorders*. 2008;43(2):135-53. doi: 10.1080/13682820701862228. PubMed PMID:
307 18283594.
- 308 9. Mitchell C, Bowen A, Tyson S, Conroy P. A feasibility randomized controlled trial of
309 ReaDySpeech for people with dysarthria after stroke. *Clinical Rehabilitation*.
310 2018;32(8):1037-46. Epub 20171226. doi: 10.1177/0269215517748453. PubMed PMID:
311 29278019; PubMed Central PMCID: PMC6088453.
- 312 10. Kiran S, Thompson CK. Neuroplasticity of Language Networks in Aphasia: Advances,
313 Updates, and Future Challenges. *Frontiers in Neurology*. 2019;10:295. Epub 20190402. doi:
314 10.3389/fneur.2019.00295. PubMed PMID: 31001187; PubMed Central PMCID:
315 PMC6454116.
- 316 11. Robertson SJ, Thomson F. Speech therapy in Parkinson's disease: a study of the efficacy
317 ad long term effects of intensive treatment. *British Journal of Disorders of Communication*.
318 1984;19(3):213-24. doi: 10.3109/13682828409029837. PubMed PMID: 6508992.

- 319 12. Tamayo-Serrano P, Garbaya S, Bouakaz S, Blazevic P. A Game-Based Rehabilitation
320 Therapy for Post-Stroke Patients: An Approach for Improving Patient Motivation and
321 Engagement. *IEEE Systems, Man, and Cybernetics Magazine*. 2020;6(4):54-62. doi:
322 10.1109/MSMC.2020.3002519.
- 323 13. Avan A, Digaleh H, Di Napoli M, Stranges S, Behrouz R, Shojaeianbabaei G, et al.
324 Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an
325 ecological analysis from the Global Burden of Disease Study 2017. *BMC Med*.
326 2019;17(1):191. Epub 20191024. doi: 10.1186/s12916-019-1397-3. PubMed PMID:
327 31647003; PubMed Central PMCID: PMC6813111.
- 328 14. Dobkin BH, Dorsch A. New evidence for therapies in stroke rehabilitation. *Current*
329 *atherosclerosis reports*. 2013;15(6):1-9. doi: 10.1007/s11883-013-0331-y. PubMed PMID:
330 23591673; PubMed Central PMCID: PMC3679365.
- 331 15. Fairburn CG, Patel V. The impact of digital technology on psychological treatments and
332 their dissemination. *Behaviour Research and Therapy*. 2017;88:19-25. doi:
333 <https://doi.org/10.1016/j.brat.2016.08.012>.
- 334 16. Abbadessa G, Brigo F, Clerico M, De Mercanti S, Trojsi F, Tedeschi G, et al. Digital
335 therapeutics in neurology. *Journal of Neurology*. 2022;269(3):1209-24. Epub 20210520. doi:
336 10.1007/s00415-021-10608-4. PubMed PMID: 34018047; PubMed Central PMCID:
337 PMC68136262.
- 338 17. Tăut D, Pinteă S, Roovers J-PWR, Mañanas M-A, Băban A. Play seriously: Effectiveness
339 of serious games and their features in motor rehabilitation. A meta-analysis.
340 *NeuroRehabilitation*. 2017;41:105-18. doi: 10.3233/NRE-171462.
- 341 18. Fu MJ, Knutson JS, Chae J. Stroke Rehabilitation Using Virtual Environments. *Physical*
342 *Medicine and Rehabilitation Clinics*. 2015;26(4):747-57. doi: 10.1016/j.pmr.2015.06.001.

- 343 19. Valentin LSS. Can Digital Games Be a Way of Improving the Neuroplasticity in Stroke
344 Damage? Can the Adult Brain Grow New Cells or Rewire Itself in Response to a New
345 Experience? *Open Journal of Medical Psychology*. 2017;6(2):153-65. doi:
346 10.4236/ojmp.2017.62013.
- 347 20. Suchak P, Ameer K, Gaylard J, Newman J, Ali K. Improving patients experience in a
348 neuro-rehabilitation unit using tablet computers. *European Journal for Person Centered*
349 *Healthcare*. 2016;4(2):289-95. doi: <http://dx.doi.org/10.5750/ejpch.v4i2.1082>.
- 350 21. Macoir J, Lavoie M, Routhier S, Bier N. Key Factors for the Success of Self-
351 Administered Treatments of Poststroke Aphasia Using Technologies. *Telemedicine and e-*
352 *Health*. 2019;25(8):663-70. doi: 10.1089/tmj.2018.0116. PubMed PMID: 30142032.
- 353 22. Mitchell C, Bowen A, Tyson S, Butterfint Z, Conroy P. Interventions for dysarthria due
354 to stroke and other adult-acquired, non-progressive brain injury. *Cochrane Database of*
355 *Systematic Reviews*. 2017;(1). doi: 10.1002/14651858.CD002088.pub3. PubMed PMID:
356 CD002088.
- 357 23. World Medical A. World Medical Association Declaration of Helsinki: ethical principles
358 for medical research involving human subjects. *JAMA*. 2013;310(20):2191-4. doi:
359 10.1001/jama.2013.281053. PubMed PMID: 24141714.
- 360 24. Ko SB, Park HK, Kim BM, Heo JH, Rha JH, Kwon SU, et al. 2019 Update of the Korean
361 Clinical Practice Guidelines of Stroke for Endovascular Recanalization Therapy in Patients
362 with Acute Ischemic Stroke. *Journal of stroke*. 2019;21(2):231-40. Epub 20190417. doi:
363 10.5853/jos.2019.00024. PubMed PMID: 30991800; PubMed Central PMCID:
364 PMCPMC6549067.
- 365 25. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D,
366 et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient
367 Ischemic Attack: A Guideline From the American Heart Association/American Stroke

- 368 Association. *Stroke*. 2021;52(7):e364-e467. Epub 20210524. doi:
369 10.1161/STR.0000000000000375. PubMed PMID: 34024117.
- 370 26. Kim HH, editor Perceptual, acoustical, and physiological tools in ataxic dysarthria
371 management: a case report. Proceedings of the KSPS conference; 1996: The Korean Society
372 Of Phonetic Sciences And Speech Technology.
- 373 27. Lousada M, Jesus LMT, Hall A, Joffe V. Intelligibility as a clinical outcome measure
374 following intervention with children with phonologically based speech–sound disorders.
375 *International Journal of Language & Communication Disorders*. 2014;49(5):584-601. doi:
376 <https://doi.org/10.1111/1460-6984.12095>.
- 377 28. Kim YT, Park H, Kang JK, Kim JA, Shin MJ, Kim S-J, et al. Validity and reliability
378 analyses for the development of Urimal Test of Articulation and Phonology-2.
379 *Communication Sciences & Disorders*. 2018;23(4):959-70. doi: 10.12963/csd.18545.
- 380 29. Namasivayam AK, Huynh A, Granata F, Law V, van Lieshout P. PROMPT intervention
381 for children with severe speech motor delay: a randomized control trial. *Pediatric Research*.
382 2021;89(3):613-21. Epub 20200501. doi: 10.1038/s41390-020-0924-4. PubMed PMID:
383 32357364; PubMed Central PMCID: PMCPMC7979536.
- 384 30. Shin MJ, Kim, J. O., Lee, S. B., & Lee, S. Y. Speech mechanism screening test. Seoul:
385 Hakjisa; 2010.
- 386 31. Ziegler W. Task-related factors in oral motor control: speech and oral diadochokinesis in
387 dysarthria and apraxia of speech. *Brain and language*. 2002;80(3):556-75. doi:
388 10.1006/brln.2001.2614. PubMed PMID: 11896657.
- 389 32. Kwon YG, Do KH, Park SJ, Chang MC, Chun MH. Effect of Repetitive Transcranial
390 Magnetic Stimulation on Patients With Dysarthria After Subacute Stroke. *Annals of*
391 *rehabilitation medicine*,. 2015;39(5):793-9. Epub 20151026. doi: 10.5535/arm.2015.39.5.793.
392 PubMed PMID: 26605178; PubMed Central PMCID: PMCPMC4654087.

- 393 33. Oh MS, Yu K-H, Lee J-H, Jung S, Ko I-S, Shin J-H, et al. Validity and Reliability of a
394 Korean Version of the National Institutes of Health Stroke Scale. *Journal of Clinical*
395 *Neurology*. 2012;8(3):177-83. doi: 10.3988/jcn.2012.8.3.177.
- 396 34. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of
397 PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders.*
398 *Patient Health Questionnaire*. *JAMA*. 1999;282(18):1737-44. doi:
399 10.1001/jama.282.18.1737. PubMed PMID: 10568646.
- 400 35. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized
401 anxiety disorder: the GAD-7. *Archives of internal medicine*. 2006;166(10):1092-7. doi:
402 10.1001/archinte.166.10.1092. PubMed PMID: 16717171.
- 403 36. Lee Y-K, Nam H-S, Chuang L-H, Kim K-Y, Yang H-K, Kwon I-S, et al. South Korean
404 time trade-off values for EQ-5D health states: modeling with observed values for 101 health
405 states. *Value in health*. 2009;12(8):1187-93. doi: 10.1111/j.1524-4733.2009.00579.x.
- 406 37. Compeau DR, Higgins CA. Computer Self-Efficacy: Development of a Measure and
407 Initial Test. *MIS Quarterly*. 1995;19(2):189-211. doi: 10.2307/249688.
- 408 38. Brooke JB, editor *SUS: A 'Quick and Dirty' Usability Scale*1996.
- 409 39. Moon j-H, Won Y-S. The Effects of Orofacial Exercises Program using Smart Phone on
410 Swallowing Function and Tongue Strength in Acute Stroke Patients with Dysphagia. *The*
411 *Journal of the Korea Institute of Electronic Communication Sciences*. 2016;11(10):995-1002.
412 doi: <https://doi.org/10.13067/JKIECS.2016.11.10.995>.
- 413 40. Wang YT, Kent RD, Duffy JR, Thomas JE. Analysis of Diadochokinesis in Ataxic
414 Dysarthria Using the Motor Speech Profile Program™. *Folia Phoniatica et Logopaedica*.
415 2009;61(1):1-11. doi: 10.1159/000184539.

- 416 41. Kent RD, Weismer G, Kent JF, Vorperian HK, Duffy JR. Acoustic studies of dysarthric
417 speech: methods, progress, and potential. *Journal of communication disorders*.
418 1999;32(3):141-86. doi: 10.1016/s0021-9924(99)00004-0. PubMed PMID: 10382143.
- 419 42. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the
420 analysis of psychiatric clinical trials. *American Journal of Psychiatry*. 2009;166(6):639-41.
421 doi: 10.1176/appi.ajp.2009.09040458. PubMed PMID: 19487398.
- 422 43. Bislick LP, Weir PC, Spencer K, Kendall D, Yorkston KM. Do principles of motor
423 learning enhance retention and transfer of speech skills? A systematic review. *Aphasiology*.
424 2012;26(5):709-28. doi: 10.1080/02687038.2012.676888.
- 425 44. Maas E, Robin DA, Hula SNA, Freedman SE, Wulf G, Ballard KJ, et al. Principles of
426 motor learning in treatment of motor speech disorders. *American Journal of Speech-*
427 *Language Pathology*. 2008;17(3):277-98. doi: [https://doi.org/10.1044/1058-0360\(2008/025\)](https://doi.org/10.1044/1058-0360(2008/025)).
- 428 45. Finch E, Rumbach AF, Park S. Speech pathology management of non-progressive
429 dysarthria: a systematic review of the literature. *Disability and rehabilitation*.
430 2020;42(3):296-306. Epub 20181004. doi: 10.1080/09638288.2018.1497714. PubMed
431 PMID: 30286661.
- 432 46. Chiaramonte R, Pavone P, Vecchio M. Speech rehabilitation in dysarthria after stroke: a
433 systematic review of the studies. *Eur J Phys Rehabil Med*. 2020;56(5):547-62. Epub
434 20200519. doi: 10.23736/s1973-9087.20.06185-7. PubMed PMID: 32434313.
- 435 47. Mahler LA, Ramig LO. Intensive treatment of dysarthria secondary to stroke. *Clinical*
436 *Linguistics & Phonetics*. 2012;26(8):681-94. doi: 10.3109/02699206.2012.696173.
- 437 48. Park S, Theodoros D, Finch E, Cardell E. Be Clear: A New Intensive Speech Treatment
438 for Adults With Nonprogressive Dysarthria. *American Journal of Speech-Language*
439 *Pathology*. 2016;25(1):97-110. doi: 10.1044/2015_ajslp-14-0113. PubMed PMID: 26882004.

- 440 49. Wenke RJ, Cornwell P, Theodoros DG. Changes to articulation following LSVT® and
441 traditional dysarthria therapy in non-progressive dysarthria. *International Journal of Speech-*
442 *Language Pathology*. 2010;12(3):203-20. doi: 10.3109/17549500903568468.
- 443 50. Beijer LJ, Rietveld ACM, Ruiter MB, Geurts ACH. Preparing an E-learning-based
444 Speech Therapy (EST) efficacy study: Identifying suitable outcome measures to detect
445 within-subject changes of speech intelligibility in dysarthric speakers. *Clinical Linguistics &*
446 *Phonetics*. 2014;28(12):927-50. doi: 10.3109/02699206.2014.936627.
- 447 51. Coleman ER, Moudgal R, Lang K, Hyacinth HI, Awosika OO, Kissela BM, et al. Early
448 Rehabilitation After Stroke: a Narrative Review. *Current atherosclerosis reports*.
449 2017;19(12):1-12. Epub 20171107. doi: 10.1007/s11883-017-0686-6. PubMed PMID:
450 29116473; PubMed Central PMCID: PMC5802378.
- 451 52. Spencer KA, Brown KA, editors. *Dysarthria following stroke*. Seminars in speech and
452 language; 2018: Thieme Medical Publishers.
- 453 53. Behrman A, Rutledge J, Hembree A, Sheridan S. Vocal hygiene education, voice
454 production therapy, and the role of patient adherence: a treatment effectiveness study in
455 women with phonotrauma. *Journal of Speech, Language, and Hearing Research*.
456 2008;51(2):350-66. doi: [https://doi.org/10.1044/1092-4388\(2008/026\)](https://doi.org/10.1044/1092-4388(2008/026)).
- 457 54. Hapner E, Portone-Maira C, Johns MM. A Study of Voice Therapy Dropout. *Journal of*
458 *Voice*. 2009;23(3):337-40. doi: <https://doi.org/10.1016/j.jvoice.2007.10.009>.
- 459 55. van Leer E, Connor NP. Predicting and influencing voice therapy adherence using social-
460 cognitive factors and mobile video. *American journal of speech-language pathology*.
461 2015;24(2):164-76. doi: https://doi.org/10.1044/2015_AJSLP-12-0123.
- 462 56. van Leer E, Connor NP. Patient perceptions of voice therapy adherence. *Journal of Voice*.
463 2010;24(4):458-69. doi: <https://doi.org/10.1016/j.jvoice.2008.12.009>.

- 464 57. Kamoen O, Maqueda V, Yperzeele L, Pottel H, Cras P, Vanhooren G, et al. Stroke coach:
465 a pilot study of a personal digital coaching program for patients after ischemic stroke. *Acta*
466 *Neurologica Belgica*. 2020;120(1):91-7. Epub 20191107. doi: 10.1007/s13760-019-01218-z.
467 PubMed PMID: 31701472.
- 468 58. Oyake K, Suzuki M, Otaka Y, Tanaka S. Motivational Strategies for Stroke
469 Rehabilitation: A Descriptive Cross-Sectional Study. *Frontiers in neurology*. 2020;11:553.
470 Epub 20200610. doi: 10.3389/fneur.2020.00553. PubMed PMID: 32587572; PubMed Central
471 PMCID: PMC7297944.
- 472 59. Bakker M, Beijer L, Rietveld T. Considerations on Effective Feedback in Computerized
473 Speech Training for Dysarthric Speakers. *Telemedicine and e-Health*. 2019;25(5):351-8.
474 Epub 20180803. doi: 10.1089/tmj.2018.0050. PubMed PMID: 30074851.
- 475 60. Ramsberger G, Marie B. Self-administered cued naming therapy: A single-participant
476 investigation of a computer-based therapy program replicated in four cases. *American*
477 *Journal of Speech-Language Pathology*. 2007;16(4):343-58. doi:
478 [https://doi.org/10.1044/1058-0360\(2007/038\)](https://doi.org/10.1044/1058-0360(2007/038)).
- 479 61. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart
480 Disease and Stroke Statistics—2022 Update: A Report From the American Heart
481 Association. *Circulation*. 2022;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052.

TIMEPOINT	STUDY PERIOD				Close-out <i>Post-study</i>
	Enrolment	Allocation	Post-allocation		
	Pre-baseline	Pre-baseline	<i>Baseline</i>	<i>4 weeks</i>	
ENROLMENT:					
<i>Eligibility screen</i>	X				
<i>Informed consent</i>	X				
<i>Allocation</i>		X			
INTERVENTIONS:					
<i>Usual care</i>					
<i>D-ST01 + usual care</i>					
ASSESSMENTS:					
Speech intelligibility			X	X	
Percentage of consonants correct			X	X	
Oral mechanism			X	X	
Oral-diadochokinetic			X	X	
Voice measures			X	X	
National Institute of Health Stroke Scale			X	X	
Depression			X	X	
Anxiety			X	X	
Quality of Life			X	X	
Self-Efficacy			X	X	
System usability					X

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.16.22278857>; this version posted August 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Fig2